IPCA Laboratories Limited Earnings Summary — Q1 FY2027
Ipca Laboratories Delivers Strong Q1 FY27 with 80% Consolidated Net Profit Growth and Robust Margin Expansion
Quarterly Business Intelligence
AI Quarterly Scorecard™
Computed deterministically from the last 10 reported quarters.
Quarterly Business Momentum
- Revenue grew 16.7% sequentially in Q1 FY2027.
- Revenue of ₹2,788 Cr is 20.8% higher year-on-year.
- Revenue has compounded at 15.1% annualised over the last 10 quarters.
- Revenue is at its highest level in 10 quarters.
- Net profit has reached its highest level in 10 quarters.
- Net profit of ₹402 Cr is 72.3% above the same quarter last year.
- Profit growth is outpacing revenue growth, pointing to positive operating leverage.
- Net profit has compounded at 133.6% annualised across the period.
- Operating margin stands at 24.0% in Q1 FY2027.
- Operating margin expanded by 597 bps year-on-year.
- Over the last two years operating margin has expanded by 524 bps.
- PBT margin is 20.5%.
- Expense growth of 12.0% remained below revenue growth of 20.8%.
- Operating profit of ₹670 Cr is 60.8% higher year-on-year.
- Operating leverage continues to improve.
- 6 of the last 6 measured quarters delivered year-on-year revenue growth.
- Overall quarterly business momentum scores 84/100 (Strong) on the latest 10 quarters.
- Business momentum remains positive heading into the next quarter.
Quarterly Financials
Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %
| Metric | Trend | Latest Q1 FY2027 | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Improving | 2,788 | 2,388 | 2,393 | 2,557 | 2,309 | 2,247 | 2,245 | 2,355 | 2,093 | 2,033 |
| Expenses | Stable | 2,119 | 1,905 | 1,859 | 2,012 | 1,892 | 1,818 | 1,782 | 1,913 | 1,700 | 1,711 |
| Operating Profit | Improving | 670 | 484 | 533 | 545 | 416 | 429 | 463 | 441 | 393 | 322 |
| Operating Margin | Improving | 24.0% | 20.3% | 22.3% | 21.3% | 18.0% | 19.1% | 20.6% | 18.8% | 18.8% | 15.8% |
| Other Income | Volatile | 25 | 48 | 38 | -30 | 33 | -179 | 20 | 26 | 21 | -118 |
| Interest | Softening | 12 | 20 | 18 | 20 | 19 | 22 | 17 | 23 | 24 | 29 |
| Depreciation | Stable | 111 | 107 | 108 | 103 | 100 | 100 | 98 | 100 | 99 | 98 |
| Profit Before Tax | Strong Uptrend | 572 | 404 | 446 | 392 | 331 | 128 | 368 | 345 | 290 | 77 |
| Tax | Improving | 149 | 95 | 82 | 108 | 96 | 62 | 91 | 99 | 91 | 74 |
| Net Profit | Strong Uptrend | 402 | 299 | 326 | 283 | 233 | 68 | 248 | 229 | 192 | 60 |
| Net Margin | Volatile | 14.4% | 12.5% | 13.6% | 11.1% | 10.1% | 3.0% | 11.1% | 9.7% | 9.2% | 2.9% |
Key Takeaways
- Consolidated revenue from operations grew 21% YoY to ₹2,788.10 crores, driven by strong performance in both formulations and APIs.
- Export income surged by 34% standalone, with institutional formulations and API exports showing significant momentum.
- Consolidated EBITDA margins expanded sharply to 22.88% from 18.39% in the same quarter last year, reflecting improved operational efficiency.
- The domestic formulations segment maintained healthy growth, up 13% YoY to ₹1,082.12 crores.
- The company has approved the amalgamation of Krebs Biochemicals & Industries Ltd. into Ipca Laboratories, effective April 1, 2026, pending final regulatory approvals.
- Profitability benefited from a sharp reduction in finance costs, which fell 58% on a standalone basis due to debt optimization.
- Exceptional items from the prior year (labor code impacts and EU fines) did not recur, contributing to the clean YoY profit jump.
Management Guidance
Management continues to focus on vertical integration and cost leadership through its API segment while diversifying into non-US markets to mitigate regulatory risks. The integration of recent acquisitions like Unichem and the proposed Krebs merger are central to the current strategy.
Sentiment Shift
Improving
The significant margin expansion and robust export growth indicate a successful navigation out of the prior year's regulatory and integration-related margin pressures.
Outlook
The company appears well-positioned to sustain double-digit growth, supported by its cost-advantaged API business and a recovering export formulation segment. The focus remains on the formal integration of subsidiaries to realize synergies.
From the Annual Report (Key Quotes)
“Standalone EBITDA margin (before forex (gain)/loss and other income) @ 26.27% in Q1 FY27 as against @ 23.82% in Q1 FY26.”
“It was resolved to amalgamate M/s. Krebs Biochemicals & Industries Ltd. with the Company, subject to necessary consents/approvals.”
“Ipca is vertically integrated and produces Finished Dosage Forms (FDFs) and Active Pharmaceutical Ingredients (APIs).”
Official Quarterly Documents
Ask AI about this quarter
This summary is AI-generated from IPCA Laboratories Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.